Pliant Therapeutics PLRX

$ 3.08 -6.53%

Quarterly report 2024-Q3
added 11-07-2024

Pliant Therapeutics Balance Sheet 2011-2025 | PLRX

Annual Balance Sheet Pliant Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-51.9 M	-21.3 M	-44.5 M	-50.6 M	-85.4 M	-60.4 M	-	-	-	-	-	-	-
Long Term Debt	10.1 M	9.93 M	5.32 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.32 M	2.46 M	1.87 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	866 K	111 M	62.3 M	-	-	-	-	-	-	-
Total Current Liabilities	28.5 M	23.9 M	16.8 M	11.6 M	-	-	-	-	-	-	-	-	-
Total Liabilities	38.6 M	37.3 M	22.2 M	12.5 M	119 M	67.4 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-500 M	-338 M	-215 M	-118 M	-76.3 M	-71.5 M	-	-	-	-	-	-	-
Total Assets	512 M	351 M	221 M	296 M	119 M	66.5 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	63.2 M	33.7 M	51.7 M	50.9 M	85.8 M	60.9 M	-	-	-	-	-	-	-
Book Value	474 M	313 M	199 M	283 M	-435 K	-882 K	-	-	-	-	-	-	-
Total Shareholders Equity	474 M	313 M	199 M	283 M	-76.3 M	-71.5 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Pliant Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	30.1 M	30.1 M	30 M	10.1 M	10 M	9.99 M	9.96 M	9.93 M	9.9 M	9.87 M	4.92 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	99.8 M	91.1 M	84.3 M	38.6 M	37.4 M	41.8 M	36 M	37.3 M	40.2 M	36.8 M	23.2 M	22.2 M	13.7 M	11.7 M	11.1 M	12.5 M	12.5 M	12.5 M	12.5 M	9.08 M	9.08 M	9.08 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-660 M	-603 M	-547 M	-500 M	-459 M	-417 M	-376 M	-338 M	-303 M	-273 M	-243 M	-215 M	-191 M	-164 M	-141 M	-118 M	-118 M	-118 M	-118 M	-76.3 M	-76.3 M	-76.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	446 M	484 M	522 M	512 M	540 M	575 M	598 M	351 M	377 M	185 M	197 M	221 M	234 M	256 M	275 M	296 M	296 M	296 M	296 M	119 M	119 M	119 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	79.6 M	80.4 M	114 M	63.2 M	57.7 M	55 M	103 M	33.7 M	44.6 M	25.1 M	32.5 M	51.7 M	45.2 M	35.2 M	50.8 M	50.9 M	50.9 M	50.9 M	50.9 M	85.8 M	85.8 M	85.8 M	-	60.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	346 M	393 M	437 M	474 M	503 M	533 M	562 M	313 M	337 M	148 M	174 M	199 M	220 M	244 M	264 M	283 M	283 M	283 M	283 M	110 M	110 M	110 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	346 M	393 M	437 M	474 M	503 M	533 M	562 M	313 M	337 M	148 M	174 M	199 M	220 M	244 M	264 M	283 M	283 M	283 M	283 M	-76.3 M	-76.3 M	-76.3 M	-86.5 M	-71.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency